Literature DB >> 11140693

Expression of mouse apolipoprotein SAA1.1 in CE/J mice: isoform-specific effects on amyloidogenesis.

J Yu1, H Zhu, J T Guo, F C de Beer, M S Kindy.   

Abstract

Amyloid A (AA) amyloid deposition in mice is dependent upon isoform-specific effects of the serum amyloid A (SAA) protein. In type A mice, SAA1.1 and SAA2.1 are the major apolipoprotein-SAA isoforms found on high-density lipoproteins. During inflammation, both isoforms are increased 1000-fold, but only SAA1.1 is selectively deposited into amyloid fibrils. Previous studies showed that the CE/J mouse strain is resistant to amyloid induction. This resistance is not due to a deficiency in SAA synthesis, but is probably related to the unusual SAA isoform present. The CE/J mouse has a single acute-phase SAA protein (SAA2.2), which is a composite of the SAA1.1 and SAA2.1, with an amino terminus similar to the nonamyloidogenic SAA2.1. Recently, genetic experiments suggested that the SAA2.2 isoform might provide protection from amyloid deposition. To determine the amyloidogenic potential of the CE/J mouse, we generated SAA adenoviral vectors to express the various isoforms in vitro and in vivo. Purified recombinant SAA proteins demonstrated that SAA1.1 was fibrillogenic in vitro, whereas SAA2.2 was unable to form fibrils. Incubation of increasing concentrations of the nonamyloidogenic SAA2.2 protein with the amyloidogenic SAA1.1 did not inhibit the fibrillogenic nature of SAA1.1, or alter its ability to form extensive fibrils. Injection of the mouse SAA1.1 or SAA2.2 adenoviral vectors into mice resulted in isoform-specific expression of the SAA proteins. Amyloid induction after viral expression of the SAA1.1 protein resulted in the deposition of amyloid fibrils in the CE/J mouse, whereas SAA2.2 expression had no effect. Similar expression of the SAA2.2 protein in C57BL/6 mice did not alter amyloid deposition. These data demonstrate that the failure of the CE/J mouse to deposit amyloid is due to the structural inability of the SAA2.2 to form amyloid fibrils. This mouse provides a unique system to test the amyloidogenic potential of altered SAA proteins and to determine the important structural features of the protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140693     DOI: 10.1038/labinvest.3780191

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

1.  Serum amyloid A: an ozone-induced circulating factor with potentially important functions in the lung-brain axis.

Authors:  Michelle A Erickson; Joseph Jude; Hengjiang Zhao; Elizabeth M Rhea; Therese S Salameh; William Jester; Shelley Pu; Jenna Harrowitz; Ngan Nguyen; William A Banks; Reynold A Panettieri; Kelly L Jordan-Sciutto
Journal:  FASEB J       Date:  2017-05-22       Impact factor: 5.191

2.  SAA does not induce cytokine production in physiological conditions.

Authors:  Myung-Hee Kim; Maria C de Beer; Joanne M Wroblewski; Nancy R Webb; Frederick C de Beer
Journal:  Cytokine       Date:  2012-11-17       Impact factor: 3.861

3.  Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel.

Authors:  Limin Wang; Hilal A Lashuel; Thomas Walz; Wilfredo Colon
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

4.  Uncovering the universality of self-replication in protein aggregation and its link to disease.

Authors:  Georg Meisl; Catherine K Xu; Jonathan D Taylor; Thomas C T Michaels; Aviad Levin; Daniel Otzen; David Klenerman; Steve Matthews; Sara Linse; Maria Andreasen; Tuomas P J Knowles
Journal:  Sci Adv       Date:  2022-08-12       Impact factor: 14.957

5.  Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.

Authors:  Saipraveen Srinivasan; Sanket Patke; Yun Wang; Zhuqiu Ye; Jeffrey Litt; Sunit K Srivastava; Maria M Lopez; Dmitry Kurouski; Igor K Lednev; Ravi S Kane; Wilfredo Colón
Journal:  J Biol Chem       Date:  2012-12-05       Impact factor: 5.157

6.  Serum amyloid A3 is a high density lipoprotein-associated acute-phase protein.

Authors:  Lisa R Tannock; Maria C De Beer; Ailing Ji; Preetha Shridas; Victoria P Noffsinger; Laura den Hartigh; Alan Chait; Frederick C De Beer; Nancy R Webb
Journal:  J Lipid Res       Date:  2017-12-15       Impact factor: 5.922

7.  Pathogenetic mechanisms of amyloid A amyloidosis.

Authors:  J Paul Simons; Raya Al-Shawi; Stephan Ellmerich; Ivana Speck; Samrina Aslam; Winston L Hutchinson; Palma P Mangione; Petra Disterer; Janet A Gilbertson; Toby Hunt; David J Millar; Shane Minogue; Karl Bodin; Mark B Pepys; Philip N Hawkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

8.  Serum Amyloid A is not obligatory for high-fat, high-sucrose, cholesterol-fed diet-induced obesity and its metabolic and inflammatory complications.

Authors:  Ailing Ji; Andrea C Trumbauer; Victoria P Noffsinger; Hayce Jeon; Avery C Patrick; Frederick C De Beer; Nancy R Webb; Lisa R Tannock; Preetha Shridas
Journal:  PLoS One       Date:  2022-04-18       Impact factor: 3.752

9.  Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection.

Authors:  Mehabaw G Derebe; Clare M Zlatkov; Sureka Gattu; Kelly A Ruhn; Shipra Vaishnava; Gretchen E Diehl; John B MacMillan; Noelle S Williams; Lora V Hooper
Journal:  Elife       Date:  2014-07-29       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.